Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

COVID-19: A Phase 1, Partially Blind, Placebo-controlled, Dose Escalation, First-in-human, Clinical Trial to Evaluate the Safety, Reactogenicity and Immunogenicity After 1 and 2 Doses of the Investigational SARS-CoV-2 mRNA Vaccine CVnCoV Administered Intramuscularly in Healthy Adults

NCT04449276 is registered in ClinicalTrials.gov with CureVac as lead sponsor.

NCT NCT04449276
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04449276 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
COVID-19: A Phase 1, Partially Blind, Placebo-controlled, Dose Escalation, First-in-human, Clinical Trial to Evaluate the Safety, Reactogenicity and Immunogenicity After 1 and 2 Doses of the Investigational SARS-CoV-2 mRNA Vaccine CVnCoV Administered Intramuscularly in Healthy Adults
Lead sponsor
CureVac
Phase
Phase 1
Overall status
Completed
Start date
June 18, 2020
Completion date
December 21, 2021
Enrollment
280 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

coronavirus, covid-19, sars-cov-2, severe acute respiratory syndrome